Open AccessSerum Lipids During Oestradiol‐Valerate/Norgestrel Treatment of Menopausal Women
Author(s) -
Christensen Niels Chr.,
Davidsen Paul Chr.,
Secher Niels J.,
Pedersen Gunnar Thomsen
Publication year - 1975
Publication title -
acta obstetricia et gynecologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.401
H-Index - 102
eISSN - 1600-0412
pISSN - 0001-6349
DOI - 10.3109/00016347509157763
Subject(s) - estradiol valerate , placebo , medicine , levonorgestrel , triglyceride , endocrinology , norgestrel , valerate , randomization , discontinuation , cholesterol , population , estrogen , clinical trial , biology , research methodology , family planning , biochemistry , butyrate , alternative medicine , environmental health , pathology , fermentation
. Thirty‐three women aged 38–56 years, all with menopausal complaints, were treated after randomization during three cycles either with oestradiolvalerate/norgestrel sequential therapy or a placebo and then during three cycles with the opposite drug. Serum cholesterol, triglycerides, glycerol as well as plasma FFA and lipoprotein electrophoresis were studied before the institution of treatment, after each cycle, and 4 weeks after the intake of the last tablet. During the treatment period the triglyceride level was significantly lower than during the placebo period, whereas no changes occurred in other parameters. The decrease was at a maximum after 8 weeks' treatment; 4 weeks after the discontinuation of treatment the levels were as before its institution. It cannot be decided whether the decrease was due to the natural oestrogen or to the gestagen.